Treprostinil (Tyvaso)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Pulmonary Arterial Hypertension, Pulmonary Hypertension Associated with Interstitial Lung Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Idiopathic Pulmonary Fibrosis · Phase 3 · under FDA review

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (11)
Idiopathic Pulmonary Fibrosis
Pulmonary Arterial Hypertension
NCT01908699 · Lung Biotechnology PBC
2013-05-31 – 2019-02-19 · Pulmonary Arterial Hypertension
What this study did
NCT01557660 · United Therapeutics
2012-06 – 2018-12 · Pulmonary Arterial Hypertension
What this study did
NCT02471183 · Actelion
2015-10-12 – 2016-12-05 · Pulmonary Arterial Hypertension
What this study did
NCT01557647 · United Therapeutics
2012-06 – 2016-06 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT05943535 · United Therapeutics
2023-10-30 – 2027-11 · Progressive Pulmonary Fibrosis, Interstitial Lung Disease
What this study did
NCT03794583 · United Therapeutics
2018-12-21 – 2022-11-29 · Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
What this study did
NCT03496623 · United Therapeutics
2018-05-08 – 2022-10-13 · Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
What this study did
Phase 2/3 (3)
Other / comorbidity
NCT07923526 · United Therapeutics
2027-03 – 2034-09 · Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
What this study did
NCT02633293 · United Therapeutics
2016-09-15 – 2021-08-01 · Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
What this study did
Phase 2 (12)
Idiopathic Pulmonary Fibrosis
NCT00703339 · Lung Biotechnology PBC
2008-06 – 2009-12 · Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
What this study did
Pulmonary Arterial Hypertension
NCT07177703 · Shanghai Zhongshan Hospital
2025-10-31 – 2027-12-31 · Pulmonary Arterial Hypertension (PAH)
What this study did
NCT05564637 · Mayo Clinic
2023-03-13 – 2024-10-30 · Pulmonary Arterial Hypertension, Interstitial Lung Disease, Healthy Adults
What this study did
NCT00705133 · Rajan Saggar
2008-07 – 2011-04 · Pulmonary Arterial Hypertension, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
What this study did
Other / comorbidity
NCT07923591 · United Therapeutics
2026-11 – 2028-05 · Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
What this study did
NCT07037836 · Bastiaan Driehuys
2025-09-29 – 2027-07-01 · COPD (Chronic Obstructive Pulmonary Disease), Hypoxemia
What this study did
NCT06969573 · University of Alberta
2025-06-05 – 2026-12-31 · COPD (Chronic Obstructive Pulmonary Disease)
What this study did
NCT03814317 · University of Florida
2020-01-30 – 2025-12-31 · Sarcoidosis, Precapillary Pulmonary Hypertension, Interstitial Lung Disease
What this study did
NCT03012646 · United Therapeutics
2017-04 – 2019-04 · Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
What this study did
NCT02178566 · Inova Health Care Services
2015-08 – 2019-01 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT02769624 · Children's Hospital Medical Center, Cincinnati
2017-02-21 – 2018-09-21 · Congenital Heart Disease
What this study did
NCT02370095 · University of North Carolina, Chapel Hill
2015-02 – 2017-11-07 · Respiratory Distress Syndrome, Adult
What this study did
Phase 1/2 (4)
Other / comorbidity
NCT03654989 · University Hospital, Grenoble
2020-01-28 – 2021-12-07 · Diabetic Foot Ulcer
What this study did
NCT03120533 · University Hospital, Grenoble
2017-06-20 – 2019-06-03 · Scleroderma, Systemic
What this study did
NCT01554540 · University Hospital, Grenoble
2012-02 – 2014-02 · Scleroderma, Systemic
What this study did
NCT01082484 · University Hospital, Grenoble
2010-01 – 2011-01 · Healthy
What this study did
Phase 1 (8)
Pulmonary Arterial Hypertension
NCT04675944 · Bial - Portela C S.A.
2018-02-28 – 2018-05-25 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT07837830 · Valley Health System
2026-09 – 2028-06 · Pulmonary Hypertension
What this study did
NCT07116681 · University of California, San Diego
2025-10-01 – 2027-07-01 · Pulmonary Hypertension
What this study did
NCT01481974 · Abhinav Humar, MD
2012-12 – 2019-11-24 · Ischemia Reperfusion Injury
What this study did
NCT01758744 · University of Colorado, Denver
2012-12 – 2016-07 · Pulmonary Hypertension, COPD
What this study did
NCT02770521 · Eli Lilly and Company
2016-05 – 2016-07 · Healthy
What this study did
NCT06193031 · Insmed Incorporated
2015-11-17 – 2015-12-18 · Healthy Volunteers
What this study did
NCT03803163 · Ascendis Pharma A/S
2015-01 – 2015-06 · Healthy Volunteers
What this study did
Phase 4 (4)
Pulmonary Arterial Hypertension
NCT03835676 · Magdi H. Yacoub
2019-05-01 – 2025-12-01 · Pulmonary Hypertension
What this study did
NCT01268553 · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
2010-08 – 2016-10-05 · Pulmonary Arterial Hypertension
What this study did
NCT00741819 · United Therapeutics
2008-09 – 2010-12 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT01305252 · Stanford University
2010-07 – 2014-09 · Hypertension, Pulmonary
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT02498444 · Stanford University
2015-09 – 2020-12 · Single Ventricle
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Early phase / not applicable (1)
Other / comorbidity
NCT07844213 · China National Center for Cardiovascular Diseases
2022-08-25 – 2025-08-31 · Congenital Heart Disease, Pulmonary Hypertension
What this study did

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Pulmonary Arterial Hypertension: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Treprostinil (Tyvaso): this drugApprovedSmall moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT00147199: Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5)
Ambrisentan (Letairis)ApprovedSmall moleculeEndothelin A receptorReliable signal
NCT01178073: Time to first adjudicated clinical failure: combination therapy vs pooled monotherapy, hazard ratio 0.502 (95% CI 0.348-0.724, p=0.0002) - 50% risk reduction
NCT00091598: 6-minute walk distance change from baseline to Week 12 (ARIES-1), placebo-corrected: +31 m with ambrisentan 5 mg (P=0.008); +51 m with ambrisentan 10 mg (P<0.001).
Bosentan (Tracleer)ApprovedSmall moleculeEndothelin receptor (ETA/ETB, dual)Partial signal
NCT00091715: Co-primary endpoints at month 6: pulmonary vascular resistance treatment effect -22.6% vs placebo (p<0.0001); 6-min walk distance (exercise capacity) treatment effect +19.1 m vs placebo (p=0.0758, not significant)
NCT00319267: AUCt for bosentan: geometric mean ratio of paediatric vs. historical-adult exposure = 0.54 (90% CI 0.37-0.78) — children had lower exposure than adults.
Epoprostenol (Flolan)
ApprovedUS marketing discontinued
Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Macitentan (Opsumit)ApprovedSmall moleculeEndothelin receptor (ETA/ETB, dual)Partial signal
NCT00660179: Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) (Up to end of treatment (data presented up to month 36)): ACT-064992 3 mg — Kaplan-Meier estimate at Month 6: 89.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 81.6 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 72.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 65.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 61.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 55 percentage of participants-Kaplan Meier | ACT-064992 10 mg — Kaplan-Meier estimate at Month 6: 92.7 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 85.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 79.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 74.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 70 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 63.2 percentage of participants-Kaplan Meier vs Placebo — Kaplan-Meier estimate at Month 6: 80.1 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 71.4 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 61.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 57.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 50.2 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 47 percentage of participants-Kaplan Meier
Riociguat (Adempas)ApprovedSmall moleculeSoluble guanylate cyclaseReliable signal
NCT00810693: 6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12 (Baseline and week 12): Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT 29.6 Meters (Standard Deviation 65.8) | Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT 31.1 Meters (Standard Deviation 79.3) vs Placebo -5.6 Meters (Standard Deviation 85.5)
Sildenafil (Revatio)ApprovedSmall moleculePDE5Partial signal
NCT00644605: The mean placebo-corrected treatment effects for 6-minute walk distance were 45 m (+13.0 percent), 46 m (+13.3 percent) and 50 m (+14.7 percent) for sildenafil doses of 20, 40 and 80 mg respectively; all comparisons achieved statistical significance (P<0.001).
Sotatercept (Winrevair)ApprovedProtein / enzyme therapeuticActivin receptor type IIA (ActRIIA)Reliable signal
NCT04576988: Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 (Baseline and Week 24): Sotatercept Plus Background PAH Therapy (DBPC Period) 34.4 meters (range 32.5 to 35.5) vs Placebo Plus Background PAH Therapy (DBPC Period) 1 meters (range -1 to 5)
NCT04896008: First death, lung transplantation or PAH-worsening hospitalization: sotatercept 17.4% (15/86) vs placebo 54.7% (47/86), HR 0.24 (95% CI 0.13 to 0.43), P<0.001; trial stopped early for efficacy (ZENITH, NEJM 2025).
Tadalafil (Adcirca)ApprovedSmall moleculePDE5Weak signal
NCT01824290: 6-minute walk distance change from baseline at Week 24: LS mean 60.48 m (SE 20.41) tadalafil vs 36.60 m (SE 20.78) placebo; placebo-adjusted mean difference 23.88 m (SD 29.11) missed
NCT00549302: 6-minute walk distance (6MWD), PHIRST-2 enrollment vs PHIRST-2 completion: tadalafil 20mg 406±67m (n=52) -> 415±80m (n=51); tadalafil 40mg 413±81m (n=59) -> 410±78m (n=59) - improvements from the 16-week PHIRST study were maintained through 52 additional weeks.
Treprostinil (Orenitram)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT00325403: Six Minute Walk Distance (6MWD) (Baseline and Week 12): UT-15C (Oral Treprostinil) — 6MWD at Baseline: 350 meters (IQR 283 to 386); 6MWD at Week 12: 370 meters (IQR 300 to 418); Change in 6MWD from Baseline to Week 12: 25 meters (IQR -16 to 63) vs Placebo — 6MWD at Baseline: 339 meters (IQR 282 to 381); 6MWD at Week 12: 343 meters (IQR 246 to 403); Change in 6MWD from Baseline to Week 12: -5 meters (IQR -41 to 49)
Treprostinil (Remodulin)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso DPI)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Yutrepia, Liquidia)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Weak signalFeatured results are safety only in this race
Extended-Release Tacrolimus (VI-0106)Phase 3Small moleculeCalcineurinnot yet gradedNo reviewed efficacy summary in this indication
Imatinib Mesylate Prodrug (IkT-001Pro)Phase 3Small moleculePDGFR (imatinib-class)not yet gradedNo reviewed efficacy summary in this indication
RalinepagPhase 3Small moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT03626688: Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001.
SeralutinibPhase 3Small moleculePDGFR/CSF1R/KIT (multi-kinase)Partial signal
NCT05934526: Change in 6MWD at Week 24 (PROSERA): seralutinib +28.2m vs placebo +13.5m; Hodges-Lehmann placebo-adjusted treatment effect +13.3m (p=0.0320), which did not meet the prespecified α=0.025 significance threshold missed
Treprostinil (L606)Phase 3Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Udenafil (Zydena)Phase 2/3Small moleculePDE5Weak signalNo reviewed efficacy summary in this indication
APL-9796Phase 2Monoclonal antibodyZIP12 (zinc transporter)not yet gradedNo reviewed efficacy summary in this indication
ROC-101Phase 2Small moleculeRho-associated kinase (ROCK, pan)not yet gradedNo reviewed efficacy summary in this indication
VasigrobartPhase 2Monoclonal antibodyPDGF-Bnot yet gradedNo reviewed efficacy summary in this indication
ZamicastatPhase 2Small moleculeDBHWeak signalNo reviewed efficacy summary in this indication
HS235Phase 1/2PeptideActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
F230
—(overall)
Small moleculeEndothelin A receptornot yet gradedNo reviewed efficacy summary in this indication
GSK6792070
—(overall)
UndisclosedActivin signallingnot yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)Weak signal
NCT01469169: Change in Pulmonary vascular resistance (PVR) from baseline to week 12: improved by -124 dyn·sec·cm-5 (95% CI, -177 to -72); 6-minute walking distance increased by 36.0 m (95% CI, 14.9 to 57.1)
PF-07868489DiscontinuedProtein / enzyme therapeuticBone morphogenetic protein 9 (BMP9)Partial signalNo reviewed efficacy summary in this indication

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Treprostinil (Tyvaso) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2COPD (Chronic Obstructive Pulmonary Disease)Active not recruiting
Est. primary completion 2026-12-31 · NCT06969573 · CT.gov ↗
What to watch
2027 (5)
July 2027 (2)
Phase 1Pulmonary HypertensionNot yet recruiting
Est. primary completion 2027-07-01 · NCT07116681 · CT.gov ↗
What to watch
Phase 2COPD (Chronic Obstructive Pulmonary Disease), HypoxemiaRecruiting
Est. primary completion 2027-07-01 · NCT07037836 · CT.gov ↗
What to watch
November 2027 (1)
Phase 3Progressive Pulmonary Fibrosis, Interstitial Lung DiseaseRecruiting
Est. primary completion 2027-11 · NCT05943535 · CT.gov ↗
What to watch
December 2027 (2)
Phase 1Pulmonary HypertensionRecruiting
Est. primary completion 2027-12 · NCT07837830 · CT.gov ↗
What to watch
Phase 2Pulmonary Arterial HypertensionNot yet recruiting
Est. primary completion 2027-12-31 · NCT07177703 · CT.gov ↗
What to watch
2028 (1)
May 2028 (1)
Phase 2Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary DiseaseNot yet recruiting
Est. primary completion 2028-05 · NCT07923591 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
Phase 3Idiopathic Pulmonary FibrosisEnrolling by invitation
Est. primary completion 2029-12 · NCT04905693 · CT.gov ↗
What to watch
2034 (1)
September 2034 (1)
Phase 2/3Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary DiseaseNot yet recruiting
Est. primary completion 2034-09 · NCT07923526 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

2 September 2026Filing acceptedFDA accepts sNDA for nebulized Tyvaso in idiopathic pulmonary fibrosis
US, FDA · United Therapeutics Corporation · Source ↗
30 March 2026Topline resultTETON-1 (NCT04708782) Phase 3 of nebulized Tyvaso in IPF met its primary endpoint
United Therapeutics Corporation · Source ↗
2 September 2025Topline resultTETON-2 (NCT05255991) Phase 3 of nebulized Tyvaso in IPF met its primary endpoint
United Therapeutics Corporation · Source ↗